Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · IEX Real-Time Price · USD
12.90
+0.08 (0.62%)
At close: May 31, 2024, 4:00 PM
11.97
-0.93 (-7.21%)
After-hours: May 31, 2024, 4:27 PM EDT
Precision BioSciences Revenue
Precision BioSciences had revenue of $57.53M in the twelve months ending March 31, 2024, with 88.25% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $17.58M with 100.27% year-over-year growth. In the year 2023, Precision BioSciences had annual revenue of $48.73M with 94.15% growth.
Revenue (ttm)
$57.53M
Revenue Growth
+88.25%
P/S Ratio
1.55
Revenue / Employee
$527,807
Employees
109
Market Cap
89.34M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
Dec 31, 2018 | 10.88M | 4.40M | 67.84% |
Dec 31, 2017 | 6.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 276.97M |
SHL Telemedicine | 57.08M |
Eton Pharmaceuticals | 35.30M |
Sensus Healthcare | 31.66M |
Ikena Oncology | 3.85M |
Oramed Pharmaceuticals | 674.00K |
Chimerix | 41.00K |
DTIL News
- 1 day ago - Precision BioSciences to Participate in Upcoming June Investor Conferences - Business Wire
- 14 days ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 23 days ago - Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement - Business Wire
- 24 days ago - Precision BioSciences to Report First Quarter Results on May 13, 2024 - Business Wire
- 24 days ago - Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 24 days ago - iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 4 weeks ago - Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 - Business Wire